AstraZeneca plc (ADR)’s Phase III Mystic trial for Imfinzi didn’t turn in the results the company was expecting and it was bad news for AZN stock. One of the primary endpoints in the trial was the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback